Franklin Biotechnology Discv Z Acc £ (FUND:B76CRG3) - Fund price - Overview

Fund Report

Franklin Biotechnology Discovery Fund Z(acc)GBP

Key Stats
Morningstar® CategorySector Equity Biotechnology
Manager NameEvan McCulloch
Inception Date04/05/2012
NAV 26/05/2017GBP 29.38
Day Change-0.27%
12 Month Yield0.00%
ISINLU0774687577
SEDOLB76CRG3
Dividend Frequency-
Net Assets (mil) 30/04/20172,520.06 USD
Wrapper AvailabilityAll
Our Minimum Initial Investment1.00 Share
Pricing FrequencyDaily
Dealing Cut off Time15:00:00
Regular InvestmentYes
Actual Initial Charge0.00%
Exit Charge0.00%
Custody ChargeYes
Fund Ongoing Charge1.33%
AMC1.00%
Fund Rebate0.05%

Morningstar Rating™

4 Stars

Morningstar Sustainability Rating

Average

Average


Sustainability Rating as of 31/03/2017

Benchmarks

Fund Benchmark

NASDAQ Biotechnology PR USD

Morningstar® Benchmark

MSCI World/Biotechnology NR USD

Growth Of 10,000 (GBP) 30/04/2017

How has this security performed
20132014201520162017
Fund61.9743.8011.55-1.247.44
Category55.0438.5413.41-3.968.49
Benchmark64.6138.9313.904.784.90
  • Fund: Franklin Biotechnology Discovery Fund Z(acc)GBP
  • Category: Sector Equity Biotechnology
  • Benchmark: MSCI World/Biotechnology NR USD
Trailing Returns % (GBP) 26/05/2017
FundCatBmark
YTD2.694.003.38
3 Years Annualised18.3417.1419.12
5 Years Annualised22.5221.7227.23
10 Years Annualised---

Morningstar SRRI

Lower Risk
Higher Risk
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Potentially Lower ReturnsPotentially Higher Returns
Source: Morningstar

Investment Objective

The Fund’s investment objective is capital appreciation. The Fund invests principally in equity securities of biotechnology companies and discovery research firms (including small to mid-sized companies) located in the US and other countries, and to a lesser extent in debt securities of any type of issuers worldwide.

Portfolio Profile30/04/2017

Morningstar Style Box®

Equity Style

Large, Mid, SmallSize
Value, Blend, Growth
Style
Top Holdings
NameSector%
IncreaseDecreaseNew since last portfolio
Celgene Corp Healthcare9.26
Biogen Inc Healthcare6.26
Alexion Pharmaceuticals Inc Healthcare5.86
Incyte Corp Healthcare5.63
IncreaseTesaro Inc Healthcare5.47
Asset Allocation %
LongShortNet
Stocks92.850.0092.85
Bonds0.000.000.00
Cash6.040.006.04
Other1.110.001.11
Top Stock Regions
Region%
United States96.70
United Kingdom0.94
Middle East0.89
Canada0.69
Eurozone0.62
Top Stock Sectors
Stock Sector%
Healthcare100.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.